BR9911224A - Métodos para redução dos nìveis de homocisteìna e proteìna c-reativa - Google Patents

Métodos para redução dos nìveis de homocisteìna e proteìna c-reativa

Info

Publication number
BR9911224A
BR9911224A BR9911224-8A BR9911224A BR9911224A BR 9911224 A BR9911224 A BR 9911224A BR 9911224 A BR9911224 A BR 9911224A BR 9911224 A BR9911224 A BR 9911224A
Authority
BR
Brazil
Prior art keywords
homocysteine
reactive protein
methods
reducing levels
levels
Prior art date
Application number
BR9911224-8A
Other languages
English (en)
Inventor
Pamela Wang Anderson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9911224A publication Critical patent/BR9911224A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"MéTODOS PARA REDUçãO DOS NìVEIS DE HOMOCISTEìNA E PROTEìNA C-REATIVA"<D>. A presente invenção refere-se a um método para a diminuição dos níveis de homocisteína e/ou de proteína C-reativa em seres humanos compreendendo a administração a um mamífero em necessidade de uma quantidade eficiente de um composto da fórmula (I) ou um sal farmacêutico ou solvato do mesmo.
BR9911224-8A 1998-06-17 1999-06-04 Métodos para redução dos nìveis de homocisteìna e proteìna c-reativa BR9911224A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8960198P 1998-06-17 1998-06-17
PCT/US1999/012604 WO1999065306A1 (en) 1998-06-17 1999-06-04 Methods for reducing levels of homocysteine and c-reactive protein

Publications (1)

Publication Number Publication Date
BR9911224A true BR9911224A (pt) 2001-02-20

Family

ID=22218549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911224-8A BR9911224A (pt) 1998-06-17 1999-06-04 Métodos para redução dos nìveis de homocisteìna e proteìna c-reativa

Country Status (18)

Country Link
US (1) US6353003B1 (pt)
EP (1) EP0966965A1 (pt)
JP (1) JP2002518296A (pt)
KR (1) KR20010052947A (pt)
CN (1) CN1305342A (pt)
AU (1) AU753035B2 (pt)
BR (1) BR9911224A (pt)
CA (1) CA2333384A1 (pt)
EA (1) EA200100049A1 (pt)
HR (1) HRP20000860A2 (pt)
HU (1) HUP0102383A3 (pt)
IL (1) IL138915A0 (pt)
NO (1) NO20006086L (pt)
PL (1) PL344841A1 (pt)
SK (1) SK18802000A3 (pt)
TR (1) TR200003713T2 (pt)
WO (1) WO1999065306A1 (pt)
ZA (1) ZA200005884B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723013A (zh) * 2003-01-06 2006-01-18 惠氏公司 雌激素受体α调节剂在治疗多发性硬化症中的用途
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
WO2004093882A1 (ja) * 2003-04-18 2004-11-04 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US20070003600A1 (en) * 2003-06-11 2007-01-04 Carolyn Moore Methods for reducing c-reactive protein
TWI386204B (zh) * 2008-04-10 2013-02-21 Mitsubishi Tanabe Pharma Corp 高半胱胺酸合成酶抑制劑

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
ES2215270T3 (es) 1993-12-21 2004-10-01 Eli Lilly And Company Inhibicion de productos terminales de glicosilacion avanzada.
US5476862A (en) 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法
US6069175A (en) 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6025373A (en) 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
US6103740A (en) 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts

Also Published As

Publication number Publication date
EA200100049A1 (ru) 2001-06-25
AU4819299A (en) 2000-01-05
TR200003713T2 (tr) 2001-04-20
US6353003B1 (en) 2002-03-05
NO20006086D0 (no) 2000-11-30
KR20010052947A (ko) 2001-06-25
AU753035B2 (en) 2002-10-03
CN1305342A (zh) 2001-07-25
IL138915A0 (en) 2001-11-25
HUP0102383A2 (hu) 2002-01-28
PL344841A1 (en) 2001-11-19
NO20006086L (no) 2000-11-30
ZA200005884B (en) 2001-10-22
HRP20000860A2 (en) 2001-10-31
SK18802000A3 (sk) 2001-09-11
WO1999065306A1 (en) 1999-12-23
CA2333384A1 (en) 1999-12-23
HUP0102383A3 (en) 2003-01-28
JP2002518296A (ja) 2002-06-25
EP0966965A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
PT784471E (pt) Metodo multifacetado para reprimir a reproducao de virus latentes em seres humanos e animais
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
DK0695189T3 (da) Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
HUP0103452A3 (en) Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds
BR9611563A (pt) Composto composição farmacêutica método de tratamento de uma doença inflamatória e ensaio para detectar inibidores de agrecanase
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
BR9915208A (pt) Preparado farmacêutico de moxifloxacina
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BR9906998A (pt) Método e composições para reduzir o envelhecimento dermatológico e para reduzir contusões
BR9911224A (pt) Métodos para redução dos nìveis de homocisteìna e proteìna c-reativa
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6,7 E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.